Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2011-10-19

Clinical Trial Update: To Demonstrate Non-inferiority of Combination of 5 mg Amlodipine/ 80 mg Valsartan to 160 mg Valsartan Alone [Phase 4]

View source ↗

Summary

Phase 4 trial update showing non-inferiority of the amlodipine/valsartan combination to valsartan alone in treating hypertension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Amlodipine/Valsartan (combination therapy) (amlodipine; valsartan)
  • VALSARTAN (Valsartan)

Snippet

Sponsor: Novartis | Conditions: Hypertension, High Blood Pressure | Phase 4 | Status: COMPLETED | Results posted: 2011-10-19